Your browser doesn't support javascript.
loading
The pharmacological actions of Danzhi-xiaoyao-San on depression involve lysophosphatidic acid and microbiota-gut-brain axis: novel insights from a systems pharmacology analysis of a double-blind, randomized, placebo-controlled clinical trial.
Zhu, Xiuqing; Wu, Shengwei; Zhou, Yufang; Xiao, Tao; Xia, Liang; Wang, Youtian; Xiao, Aixiang; Guo, Jianxiong; Zhang, Ming; Wen, Yuguan; Shang, Dewei; Yu, Lin.
Affiliation
  • Zhu X; Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
  • Wu S; Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zhou Y; Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
  • Xiao T; Department of Integrated Chinese and Western Medicine, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
  • Xia L; Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
  • Wang Y; Department of Integrated Chinese and Western Medicine, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
  • Xiao A; Department of Clinical Research, Guangdong Second Provincial General Hospital, Guangzhou, China.
  • Guo J; Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Materia Medica, Beijing, China.
  • Zhang M; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Wen Y; Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
  • Shang D; Department of Integrated Chinese and Western Medicine, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
  • Yu L; Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
J Biomol Struct Dyn ; : 1-16, 2023 Aug 26.
Article in En | MEDLINE | ID: mdl-37632305
HIGHLIGHTSThis study presents a double-blind, randomized, placebo-controlled clinical trial comparing the clinical effects of Danzhi-xiaoyao-San (DZXYS) plus selective serotonin reuptake inhibitors (SSRIs) and SSRIs alone.This study is the first system pharmacology approach to integrate multi-omics and network pharmacology and examine the clinical pharmacological mechanisms of DZXYS as an add-on therapy for depression.This study highlights that regulation of lysophosphatidic acid (LPA) and the microbiota-gut-brain axis by DZXYS plays an essential role in its antidepressant mechanisms.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Language: En Journal: J Biomol Struct Dyn Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Language: En Journal: J Biomol Struct Dyn Year: 2023 Document type: Article Affiliation country: Country of publication: